10626588

2003-07-25

Approved for use through 09/03/2007 OMB 0851-031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE mation unless it contains a valid OMB control number

Application Number

Filing Date

				i ming Dute			E000 01 E0			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)			First Named Inventor Shini		chi Yamamura et al.					
			Art Unit	Art Unit						
			Examiner Name							
				Attorney Doc	Attorney Docket Number 03500.017426					
				U.S.	PATENTS	,			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	ssue Date Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1									
If you wisl	h to a	dd additional U.S. Pater	nt citatio	n information pl	lease click	the A	dd button.	-	Add	
U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant R		Releva	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wis	h to a	dd additional U.S. Publi	shed An	olication citation	n informat	ion ple	ase click the Ad	d button	Add	1

FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No					Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ţ5
	1	0101252	wo			Microsoft Corp.		
If you wish to add additional Ecosion Patent Document citation information please click the Add button Add								

Remove NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), Τ۶ Initials* No publisher, city and/or country where published.

	1	ANDERSON, Rick, "The End of DLL Hell", XP007902262, URL http://msdn2.microsoft.com/en-us/library/ims811694(d-printer).aspx>, pp. 4, 5, 2000-01			
	2	D'SOUZA et al., 'Implementing Side by-Side Component Sharing in Applications (Expanded)', XP-007902263, URL http://msdn/zmcrosoft.com/en-us/library/tres/811700(d-printer).aspx-, p. 5, 1999-11			
	3	"Windows File Protection and Windows", XP002294085, URL http://www.microsoft.com/whdo/wniogo/dneign/whp.mspso-, 2001-1-4			
If you wish to add additional non-patent literature document citation information please click the Add button Add					
EXAMINER SIGNATURE					

Examiner Signature Date Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

16e Kinz Code of UBPTO Peter Documents at www.UBPTO_COLV or MPET 90104. 2 Enter of this that issued the document, by the involvator code (WPD)
Standard 373.) 3 "The planess patient founds in Counter's, the indicates of the year of the integer of the Emperor must precede the senial number of the patient document.

**Indicate of counterty the appropriate symbols as included on the document under WPD Standard 57.6 of possible. **Application is to place a credit number of the patient document in the place and the patient of the patient in the patient of the patient. **Application is the place a credit number of the patient in the patient is the patient. **Application is the patient in the patient patient in the patient is placed as the patient patient

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10626588			
Filing Date		2003-07-25			
First Named Inventor Shinic		shi Yamamura et al.			
Art Unit					
Examiner Name					
Attorney Docket Numb	er	03500.017426			

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no terrior part of the information disclosure statement was known to any individual designated in 37 CFR 1/50(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Non

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Frank Cire #42,419/	Date (YYYY-MM-DD)	2007-08-16
Name/Print	Frank L. Cire	Registration Number	42,419

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR.

1.14. This collection is estimated to take if hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Tradenski offices, V.S. pepariment of Commence, P. 0. Des 1450, Alexandri, V.S. 2213-1450. DO ROY SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, VA.2213-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.